My watch list  

Endo Pharmaceuticals

Endo Pharmaceuticals
HeadquartersChadds Ford, Pennsylvania

Endo became Endo Pharmaceuticals Inc. as a result of a management buyout from DuPont Merck in 1997. Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain.


  • Chief financial officer: Charles A. Rowland Jr. (as of December 2006, replacing Jeff Black) [1]
  • The company's sales force numbers 590 [1]


  • Amantadine (Symmetrel®)
  • Carbidopa with levodopa (Carbidopa/Levodopa USP)
  • Frovatriptan (Frova®)
  • Hydrocodone with acetominophen (Zydone®)
  • Hydrocodone with homatropine (Hycodan®)
  • Lidocaine (Lidoderm®)
    • Lidocaine with tetracaine (Synera®)
  • Molindone (Moban®)
  • Oxycodone with acetominophen (Percocet®, Endocet®)
  • Oxycodone with aspirin (Percodan®)
  • Oxymorphone (Opana®)


  1. a b Staff. "Endo Pharmaceuticals names new CFO", Delaware News Journal, December 6, 2006. Retrieved on 2006-12-06. 
  2. ^  Product Listing. Endo Pharmaceuticals (2006). Retrieved on 2006-12-06.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Endo_Pharmaceuticals". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE